At the Crohn's & Colitis Congress next week, we are presenting the first detailed results from a human study demonstrating device function when administered with food, potentially enabling non-fasted administration.
#IBD
#colitis
#UC
#CCCongress23
$BIOR
Sharing topline results today from the second human study in our targeted therapeutics platform for
#IBD
, showing that our capsule could be administered with food.
#drugdelivery
$BIOR
$BIOR presents data from device performance study with repeat doses in both fasted and fed states at Crohn’s & Colitis Congress
#IBD
#colitis
#UC
#CCCongress23
Thanks to all who joined the $BIOR Q2 update yesterday. The recorded webcast, latest corporate presentation, and updated investor Q&A are available here:
Dr. Shaoying Nikki Lee (Biora Therapeutics) and Dr. Kathleen Martin (CHI St. Joseph Medical Group) presenting their research on device performance in
#UC
patients at
#ACG2022
this week. View the poster here:
#IBD
#ulcerativecolitis
#GItwitter
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
Dr. Severine Vermeire's presentation at
#DDW2022
shared patient data establishing the correlation between drug levels in the colon and patient outcomes in
#UC
. It's why we are working on getting more drug to the site of disease for
#IBD
.
We’re happy to announce that $PROG is now $BIOR! Please join the live webcast of our first quarter conference call today at 1:30 Pacific / 4:30 PM Eastern.
$BIOR provides corporate update and reports fourth quarter and full-year 2023 financial results. All performance targets achieved in SAD cohorts of BT-600 clinical trial:
#IBD
#earningscall
#ClinicalTrials
We'll be at
#PDAups
in October presenting data on the autonomous triggering and injection efficiency of our systemic therapeutics platform for
#oraldelivery
of
#biologics
. Learn more:
Thanks to all who joined the $BIOR Q4 2022 update today. The latest corporate presentation and investor Q&A, which includes a guide to the new program numbers, are available here:
Why is this poster from
#DDW2022
important? It suggests multiple inflammatory pathways for
#UC
, supporting the hypothesis that combination therapy could improve overall patient outcomes.
Thanks to all who joined the $BIOR Q3 update yesterday. The recorded webcast, latest corporate presentation, and updated investor Q&A are available here:
Thanks to all who joined us for this morning's
#HCWCO
fireside chat, which included an update on
#NaviCap
clinical studies and
#BioJet
platform development. A replay of the conversation is now available on our website: